HTG Molecular Diagnostics (HTGMQ) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	0001169987
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		8,586,046
Entity File Number	001-37369
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0912294
Entity Address, Address Line One	3430 E. Global Loop
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85706
City Area Code	(877)
Local Phone Number	289-2615
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 14,614,427	$ 9,599,950
Short-term investments available-for-sale, at fair value	6,948,584	12,343,456
Accounts receivable, net of allowance of $20,315 at March 31, 2022 and December 31, 2021	749,220	2,092,466
Inventory, net of allowance of $79,339 at March 31, 2022 and $25,306 at December 31, 2021	2,022,478	1,987,753
Prepaid expenses and other	1,082,135	1,163,339
Total current assets	25,416,844	27,186,964
Operating lease right-of-use assets	1,245,045	1,345,361
Property and equipment, net	941,809	1,118,886
Other non-current assets	860,604	809,476
Total assets	28,464,302	30,460,687
Current liabilities:
Accounts payable	1,317,009	1,649,440
Accrued liabilities	1,024,984	2,022,569
Current portion of long-term debt	5,000,000	5,167,586
NuvoGen obligation - current	548,301	548,301
Operating lease liabilities - current	423,111	413,865
Other current liabilities	181,088	141,749
Total current liabilities	8,494,493	9,943,510
NuvoGen obligation - non-current, net of discount	3,725,273	3,900,880
Long-term debt, net of current portion, discount and debt issuance costs	4,046,356	5,178,629
Other non-current liabilities	929,706	1,037,844
Total liabilities	17,195,828	20,060,863
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; no shares authorized, issued and outstanding at March 31, 2022; 23,770 shares authorized, issued and outstanding at December 31, 2021		24
Common stock, $0.001 par value; 26,666,667 shares authorized at March 31, 2022 and December 31, 2021, 8,583,253 shares issued and outstanding at March 31, 2022 and 7,588,085 shares issued and outstanding at December 31, 2021	8,583	7,588
Additional paid-in-capital	226,090,840	218,723,349
Accumulated other comprehensive income (loss)	(399)	1,894
Accumulated deficit	(214,830,550)	(208,333,031)
Total stockholders’ equity	11,268,474	10,399,824
Total liabilities and stockholders' equity	$ 28,464,302	$ 30,460,687

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Accounts receivable net allowance	$ 20,315	$ 20,315
Inventory net allowance	$ 79,339	$ 25,306
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	26,666,667	26,666,667
Common stock, shares issued	8,583,253	7,588,085
Common stock, shares outstanding	8,583,253	7,588,085
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	0	23,770
Preferred stock, shares issued	0	23,770
Preferred stock, shares outstanding	0	23,770

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Product and product-related services revenue	$ 1,184,454	$ 1,435,146
Revenue, Product and Service [Extensible Enumeration]	us-gaap:ProductAndServiceOtherMember	us-gaap:ProductAndServiceOtherMember
Operating expenses:
Cost of product and product-related services revenue	$ 855,048	$ 785,200
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductAndServiceOtherMember	us-gaap:ProductAndServiceOtherMember
Selling, general and administrative	$ 4,663,011	$ 3,859,619
Research and development	1,920,430	1,372,040
Total operating expenses	7,438,489	6,016,859
Operating loss	(6,254,035)	(4,581,713)
Other income (expense):
Interest expense	(249,312)	(270,357)
Interest income	6,214	6,212
Total other income (expense)	(243,098)	(264,145)
Net loss before income taxes	(6,497,133)	(4,845,858)
Provision for income taxes	(386)	(2,449)
Net loss	$ (6,497,519)	$ (4,848,307)
Net loss per share, basic and diluted	$ (0.81)	$ (0.80)
Shares used in computing net loss per share, basic and diluted	8,011,774	6,040,752

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (6,497,519)	$ (4,848,307)
Other comprehensive loss, net of tax effect:
Foreign currency translation adjustment	(2,293)	(1,557)
Total other comprehensive loss	(2,293)	(1,557)
Comprehensive loss	$ (6,499,812)	$ (4,849,864)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	ATM Offering	Purchase Agreement	Series A Convertible Preferred Stock	Common Stock	Common StockATM Offering	Common StockPurchase Agreement	Additional Paid-In Capital	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalPurchase Agreement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2020	$ 14,484,660			$ 24	$ 5,200			$ 205,661,999			$ 5,298	$ (191,187,861)
Balance, shares at Dec. 31, 2020				23,770	5,199,997
Stock-based compensation expense	337,823							337,823
Release of restricted stock awards	1				$ 1
Release of restricted stock awards, shares					1,390
Net share settlement of restricted stock awards	(1,197)							(1,197)
Net share settlement of restricted stock award, shares					(250)
Employee stock purchase plan expense	13,115							13,115
Issuance of common stock		$ 6,855,198				$ 1,058			$ 6,854,140
Issuance of common stock, shares						1,058,045
Exercise of stock options	326							326
Exercise of stock options, shares					75
Net loss	(4,848,307)											(4,848,307)
Foreign currency translation adjustment	(1,557)										(1,557)
Balance at Mar. 31, 2021	16,840,062			$ 24	$ 6,259			212,866,206			3,741	(196,036,168)
Balance, shares at Mar. 31, 2021				23,770	6,259,257
Balance at Dec. 31, 2021	10,399,824			$ 24	$ 7,588			218,723,349			1,894	(208,333,031)
Balance, shares at Dec. 31, 2021				23,770	7,588,085
Stock-based compensation expense	251,214							251,214
Release of restricted stock awards					$ 4			(4)
Release of restricted stock awards, shares					4,148
Net share settlement of restricted stock awards	(8,129)				$ (1)			(8,128)
Net share settlement of restricted stock award, shares					(1,500)
Employee stock purchase plan expense	16,591							16,591
Issuance of common stock			$ 7,108,786				$ 834			$ 7,107,952
Issuance of common stock, shares							834,054
Conversion of Series A convertible preferred stock for common stock				$ (24)	$ 158			(134)
Conversion of Series A convertible preferred stock for common stock, shares				(23,770)	158,466
Net loss	(6,497,519)											(6,497,519)
Foreign currency translation adjustment	(2,293)										(2,293)
Balance at Mar. 31, 2022	$ 11,268,474				$ 8,583			$ 226,090,840			$ (399)	$ (214,830,550)
Balance, shares at Mar. 31, 2022					8,583,253

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
Statement Of Stockholders Equity [Abstract]
At the market offering, commissions and issuance costs	$ 0.2

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (6,497,519)	$ (4,848,307)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	185,492	197,951
Accretion of discount on NuvoGen obligation	(2,983)	(3,106)
Provision for excess inventory	59,353	4,836
Amortization of SVB Term Loan discount and issuance costs	117,727	123,010
Stock-based compensation expense	251,214	337,824
Employee stock purchase plan expense	16,591	13,115
Non-cash operating lease expense	100,316	151,831
Accrued interest on available-for-sale securities investments	(5,128)	(3,600)
Loss on abandonment and disposal of assets, net		178,925
Changes in operating assets and liabilities:
Accounts receivable	1,343,246	56,997
Inventory	(120,164)	(115,584)
Prepaid expenses and other	93,299	(401,597)
Accounts payable	(352,934)	145,309
Accrued liabilities	(1,069,543)	(336,973)
Contract liabilities	40,279	302,357
Operating lease liabilities	(98,809)	(156,249)
Net cash used in operating activities	(5,939,563)	(4,353,261)
Investing activities
Purchase of property and equipment	(8,415)	(98,509)
Maturities of available-for-sale securities	5,400,000	6,300,000
Purchase of available-for-sale securities		(8,986,169)
Net cash (used in) provided by investing activities	5,391,585	(2,784,678)
Financing activities
Proceeds from ATM Offering, net of commissions of $0.2 million		6,855,198
Proceeds from March 2022 Purchase Agreement, net of $0.4 million of issuance costs	7,207,499
Payments on NuvoGen obligation	(172,624)	(154,777)
Payments on SVB Term Loan	(1,250,000)
Payments on deferred offering costs	(38,500)
Payments on financing leases	(4,635)	(6,905)
Proceeds from exercise of stock options		326
Taxes paid for net share settlement of restricted stock awards	(8,129)	(1,197)
Payments on insurance notes	(167,586)	(165,099)
Net cash provided by financing activities	5,566,025	6,527,546
Effect of exchange rates on cash	(3,570)	(9,732)
Increase (decrease) in cash and cash equivalents	5,014,477	(620,125)
Cash and cash equivalents at beginning of period	9,599,950	22,397,812
Cash and cash equivalents at end of period	14,614,427	21,777,687
Supplemental disclosure of noncash investing and financing activities
Fixed asset purchases payable and accrued at period end		10,738
Issuance of common stock upon conversion of Series A convertible preferred stock	1,402,430
Deferred financing costs payable and accrued at period end	98,713
Supplemental cash flow information
Cash paid for interest	$ 139,846	146,161
Cash paid for taxes		$ 90

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Issuance costs	$ 0.4
ATM Offering
Underwriting discounts, commissions and issuance costs		$ 0.2
March 2022 Purchase Agreement
Issuance costs	$ 0.4

Description of Business, Basis

Description of Business, Basis of Presentation and Principles of Consolidation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Principles of Consolidation	Note 1. Description of Business, Basis of Presentation and Principles of Consolidation HTG Molecular Diagnostics, Inc. (the “Company”) is a life science company whose mission is to advance precision medicine through its innovative transcriptome-wide profiling technology. The Company derives revenue primarily from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (“NGS-based”) HTG EdgeSeq research use only (“RUO”) assays and from sample processing services performed in its VERI/O laboratory. The Company operates in one segment and its customers and distributors are located primarily in the United States and Europe. For sales to distributors, their locations may be different from the locations of the end customers. For the three months ended March 31, 2022, approximately 18% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 41% for the three months ended March 31, 2021. COVID-19 Pandemic The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the ongoing evolution of the COVID-19 pandemic, including resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes that while it has seen some recovery, this impact will continue to be seen at some level at least through the first half of 2022. The extent of this impact has varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization of studies by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has not experienced delays in its development efforts despite its efforts to prioritize the safety of its employees during this pandemic. In addition, the impact of the COVID-19 pandemic on the Company’s ability to source raw materials and other supplies has not been significant to date. However, a change in or loss of suppliers or other supply chain or distribution network partners due to the ongoing impacts of the pandemic on the global economy could adversely affect the Company’s business and the business of its vendors, partners and customers, and could result in future reductions in sales and operating results. While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date these condensed consolidated financial statements were issued and has reflected any known or expected impacts in its condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. As a result of various government programs enacted to address the ongoing impacts of COVID-19, the Company was able to qualify for and receive Employee Retention Credits (“ERC”) during the years ended December 31, 2020 and 2021. ERC benefits of approximately $0.1 million, $0.3 million, and $0.1 million were included in cost of product and product-related services revenue, selling, general and administrative and research and development, respectively, as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2021. In November 2021, the Infrastructure Investment and Jobs Act was signed into law, making wages paid after September 30, 2021 ineligible for these credits. As such, no further ERC benefits were received for the three months ended March 31, 2022. ERC benefits receivable of $0.4 million was included in prepaid expenses and other in the accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of March 31, 2022 and for the three months ended March 31, 2022 and 2021. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2022. Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these financial statements. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $214.8 million as of March 31, 2022. As of March 31, 2022, the Company had working capital of $16.9 million and long-term liabilities of $8.7 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan with Silicon Valley Bank (the “SVB Term Loan”), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). Potentially changing circumstances, including COVID-19 uncertainties, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”). These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash, including short term investments available-for-sale, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, HTG Molecular Diagnostics France, SARL, after elimination of all intercompany transactions and balances. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instrument, related consumables, sample processing services and custom RUO assay design services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top three customers accounted for 24%, 20% and 12% of the Company’s revenue for the three months ended March 31, 2022, compared with the Company’s top two customers accounting for 19% and 15% of the Company’s revenue for the three months ended March 31, 2021. The largest three customers accounted for 50%, 11% and 10% of the Company’s accounts receivable as of March 31, 2022. The largest two customers accounted for approximately 18% and 17% of the Company’s accounts receivable as of December 31, 2021. The third and fourth largest customers accounted for approximately 10% each of the Company’s accounts receivable as of December 31, 2021. One vendor accounted for 28% of the Company’s accounts payable as of March 31, 2022, compared with two vendors who accounted for 28% and 16% of the Company’s accounts payable as of December 31, 2021. The Company is also subject to supply chain risks related to the reliance on a single supplier to manufacture a subcomponent used in its HTG EdgeSeq instruments. Although there are a limited number of manufacturers for components of this type, the Company believes that other suppliers could provide similar products on comparable terms. However, a change in or loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable, allowance for doubtful accounts and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers. Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The Company’s obligation related to an asset purchase transaction with a then-common stockholder of the Company, (the “NuvoGen obligation”) had an estimated fair value of approximately $4.2 million as of March 31, 2022. This estimated fair value represents a Level 3 measurement that has been determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of March 31, 2022: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard became effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 Raw materials $ 1,952,440 $ 1,964,407 Work in process 264,553 312,803 Finished goods 622,206 447,145 Total gross inventory 2,839,199 2,724,355 Less inventory allowance (79,339 ) (25,306 ) $ 2,759,860 $ 2,699,049 Inventory of $2.0 million and $0.7 million was included in inventory – current and other non-current assets, respectively, in the condensed consolidated balance sheets as of both March 31, 2022 and December 31, 2021. For the three months ended March 31, 2022, the Company recorded a specific inventory reserve of $54,033 to adjust estimated inventory value for the projected expiration of a specific inventory item, in addition to adjustments to the provision for excess inventory of $5,320. Adjustments to the provision for excess inventory of $4,836 were recorded for the three months ended March 31, 2021. These adjustments for estimated shrinkage, obsolescence and excess inventory have been included in cost of product and product-related services revenue in the accompanying condensed consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation was $0.2 million as of both March 31, 2022 and December 31, 2021.

Fair Value Instruments

Fair Value Instruments	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 in the fair value hierarchy: March 31, 2022 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 13,966,691 $ — $ — $ 13,966,691 Investments available-for-sale at fair value Corporate debt securities — 6,948,584 — 6,948,584 Total $ 13,966,691 $ 6,948,584 $ — $ 20,915,275 December 31, 2021 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 9,083,302 $ — $ — $ 9,083,302 Investments available-for-sale at fair value Corporate debt securities — 12,343,456 — 12,343,456 Total $ 9,083,302 $ 12,343,456 $ — $ 21,426,758 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three months ended March 31, 2022 or the year ended December 31, 2021. Level 1 instruments include investments in money market funds. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities, including commercial paper and corporate bonds. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the three months ended March 31, 2022 or the year ended December 31, 2021.

Available-for-Sale Securities

Available-for-Sale Securities	3 Months Ended
	Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities as of March 31, 2022 and December 31, 2021: March 31, 2022 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities $ 6,948,584 $ — $ — $ 6,948,584 Total available-for-sale securities $ 6,948,584 $ — $ — $ 6,948,584 December 31, 2021 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities $ 12,343,456 $ — $ — $ 12,343,456 Total available-for-sale securities $ 12,343,456 $ — $ — $ 12,343,456 There were no gross unrealized losses relating to the Company’s available-for-sale securities investments as of March 31, 2022. Contractual maturities of all of the Company’s debt securities investments were less than one year as of March 31, 2022. Expected maturities may differ from contractual maturities where issuers of the securities have the right to prepay obligations without prepayment penalties.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following as of the dates indicated: March 31, December 31, 2022 2021 Furniture & fixtures $ 872,877 $ 872,877 Leasehold improvements 1,940,177 1,931,762 Equipment used in manufacturing 2,432,242 2,432,242 Equipment used in research & development 2,343,930 2,343,930 Equipment used in the field 216,218 216,218 Software 480,740 480,740 Property and equipment 8,286,184 8,277,769 Less: accumulated depreciation and amortization (7,344,375 ) (7,158,883 ) $ 941,809 $ 1,118,886 Depreciation and leasehold improvement amortization expense was approximately $0.2 million for both the three months ended March 31, 2022 and 2021.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 Accrued employee bonuses $ 276,687 $ 1,254,355 Payroll and employee benefit accruals 286,526 389,385 Accrued accounting and legal fees 145,838 47,594 Accrued product warranty 98,716 97,512 Other accrued liabilities 217,217 233,723 $ 1,024,984 $ 2,022,569

Debt Obligations

Debt Obligations	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations Current portion of long-term debt consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 SVB Term Loan $ 5,000,000 $ 5,000,000 2021 Insurance Note — 167,586 $ 5,000,000 $ 5,167,586 Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 SVB Term Loan, net of discount and debt issuance costs $ 4,046,356 $ 5,178,629 SVB Term Loan On June 24, 2020 (the “Closing Date”), the Company entered into the SVB Term Loan, by and among the Company and SVB, as lender, which provides a secured term loan in the principal amount of $10.0 million. The proceeds from the SVB Term Loan were fully funded on June 25, 2020. The SVB Term Loan bears interest at a floating rate equal to the greater of 2.50% above the Prime Rate (as defined in the Loan Agreement) and 5.75%. Interest on the SVB Term Loan is due and payable monthly in arrears. The SVB Term Loan originally required interest-only payments through June 30, 2021. As a result of the Company’s achievement of an equity milestone defined in the Loan Agreement during the quarter ended June 30, 2021, the interest-only period was extended for six months through December 31, 2021. The extended interest-only period is followed by equal monthly payments of principal and interest through the maturity date of December 1, 2023. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge), and the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the Loan Agreement. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In connection with the Loan Agreement, the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The fair value of the warrant on the date of issuance was approximately $0.4 million, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the SVB Term Loan, with a corresponding credit to additional paid in capital since the warrant met the requirements to be classified as equity. The Company included $0.5 million and $0.6 million of debt discount associated with the SVB Term Loan, resulting from fees and debt issuance costs, inclusive of the fair value of warrants issued, in long-term debt, net of current portion, discount and debt issuance costs in the as of March 31, 2022 and December 31, 2021, respectively. Amortization of the debt discount associated with the SVB Term Loan was approximately $0.1 million for both the three months ended March 31, 2022 and 2021, and was included in interest expense in the . The remaining principal repayments due under the SVB Term Loan as of March 31, 2022 are as follows for each fiscal year: 2022 $ 3,750,000 2023 5,000,000 Total SVB Term Loan payments 8,750,000 Less discount and deferred financing costs (503,644 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 9,046,356 Insurance Note On May 5, 2021, the Company entered into a new commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2021 Insurance Note”). The 2021 Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.4 million. The remaining unpaid premium balance of approximately $0.7 million has been financed at an annual rate of 3.57% and is to be repaid in nine equal monthly payments of principal and interest beginning in June 2021

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Product and Product-Related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three months ended March 31, 2022 and 2021 as follows: Three Months Ended March 31, 2022 2021 Product revenue: Instrument $ 193,186 $ 224,013 Consumables 471,214 604,382 Total product revenue 664,400 828,395 Product-related services revenue: Custom RUO assay design — 48,350 RUO sample processing 520,054 558,401 Total product-related services revenue 520,054 606,751 Total product and product-related services revenue $ 1,184,454 $ 1,435,146 As the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of Instruments and Consumables The delivery of each instrument and the related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs an instrument in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of this performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. RUO Sample Processing The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared with total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay design fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Contract Liabilities The Company may receive up-front payments from customers for custom RUO assay design and sample processing services. In addition, payments for instrument extended warranty contracts are required to be made in advance. The Company recognizes such up-front payments as contract liabilities. The contract liabilities are subsequently reduced as revenue is recognized. Contract liabilities of approximately $0.2 million were included in other current liabilities and an additional immaterial amount of contract liabilities were included in other non-current liabilities in the accompanying condensed consolidated balance sheets as of March 31, 2022, reflecting the period in which the Company expects to realize the deferred revenue. Changes in the Company’s contract liability were as follows as of the dates indicated: Product Revenue Sample Processing Total Contract Liability Balance at January 1, 2022 $ 128,529 $ 30,621 $ 159,150 Deferral of revenue 147,893 - 147,893 Recognition of deferred revenue (102,812 ) (4,800 ) (107,612 ) Balance at March 31, 2022 $ 173,610 $ 25,821 $ 199,431

Other Agreements

Other Agreements	3 Months Ended
	Mar. 31, 2022
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation Pursuant to the Company’s asset purchase agreement with NuvoGen Research, LLC (“NuvoGen”), as amended, the Company is obligated to pay NuvoGen annually the greater of $400,000 or 6% of annual revenue until the NuvoGen obligation is paid in full. In addition to the fixed quarterly payment of $100,000, there was no revenue-based amount payable as of March 31, 2022, compared with $72,624 of revenue-based payments as of December 31, 2021. There have been no modifications to the terms and conditions of the NuvoGen obligation since the disclosures made in Part II, Item 8, Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022. Remaining minimum payments to be made in 2022 and in the first quarter of 2023 as reflected in the table below include an estimate of additional revenue-based payments to be made in these quarters, estimated using actual revenue generated in the same quarter in the prior year. Remaining minimum payments include only the minimum quarterly payments to be made in each period. Actual payments could vary from what is shown in the table, to the extent that 6% of the Company’s revenue in 2022 and the first quarter of 2023 varies from the same periods in prior years and revenue in the second quarter of 2023 and later periods exceeds $400,000. The remaining minimum payments to be made to NuvoGen as of March 31, 2022 are as follows for each fiscal year: 2022 $ 375,677 2023 472,624 2024 400,000 2025 400,000 2026 400,000 2027 and beyond 2,161,168 Total NuvoGen obligation payments 4,209,469 Plus interest accretion 64,105 Total NuvoGen obligation, net $ 4,273,574 The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, which represents the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized interest accretion was $(64,105) and $(67,088)

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Note 11. Leases Operating Leases T he Company leases office space under agreements classified as operating leases. The Company’s active leases as of March 31, 2022 are for office and manufacturing space in Tucson, Arizona, which expire in 2025. The Company’s leases do not include any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. The components of lease cost for operating leases were as follows: Three Months Ended March 31, 2022 2021 Operating leases Operating lease cost $ 119,458 $ 167,679 Variable lease cost 27,526 26,151 Total rent expense $ 146,984 $ 193,830 The table below summarizes other information related to the Company’s operating leases: Three Months Ended March 31, 2022 2021 Cash paid for amounts included in measurement of operating lease liabilities $ 117,952 $ 172,095 Weighted-average remaining lease term – operating leases 2.8 0.8 Weighted-average discount rate – operating leases 5.8 % 6.3 % Remaining maturities of the Company’s operating leases, included in operating lease liabilities – current and other non-current liabilities, in the condensed consolidated balance sheets as of March 31, 2022 are as follows: 2022 $ 363,597 2023 484,719 2024 484,631 2025 40,381 Total 1,373,328 Less present value discount (108,812 ) Total operating lease liabilities 1,264,516 Less operating lease liabilities – current (423,111 ) Operating lease liabilities - non-current $ 841,405 Financing Leases The Company has computer and copier equipment leases that are classified as financing leases. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to information received by the Company from bankers regarding estimated current borrowing rates for collateralized loans with similar amount and duration as the leases. The components of lease cost for financing leases were as follows: Three Months Ended March 31, 2022 2021 Financing leases Amortization of right-of-use assets $ 4,618 $ 7,099 Interest on lease liability 1,137 1,665 Total financing lease cost $ 5,755 $ 8,764 The table below summarizes other information related to the Company’s financing leases: Three Months Ended March 31, 2022 2021 Weighted-average remaining lease term – financing leases 2.6 3.3 Weighted-average discount rate – financing leases 9.77 % 9.77 % As of March 31, 2022, remaining maturities of the Company’s financing leases are as follows: 2022 $ 14,943 2023 18,396 2024 16,080 Total 49,419 Less present value discount (5,943 ) Financing lease liabilities, net $ 43,476 Financing lease liabilities net of discount of $16,038 and $27,438 were included in other current liabilities and other non-current liabilities, respectively, and financing right-of-use assets of $39,034 were included in property and equipment, net, in the condensed consolidated balance sheets as of March 31, 2022.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Share	Note 12. Net Loss Per Share Basic loss per common share is computed by dividing net loss allocable to common stockholders by the weighted average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per In connection with the March 2022 Purchase Agreement (see Note 13), the Company issued and sold pre-funded warrants exercisable for an aggregate of 2,410,933 shares of common stock. Each pre-funded warrant has an exercise price of $0.001 per share and does not expire until exercised in full. As the remaining shares underlying the pre-funded warrants are issuable for nominal consideration of $0.001 per share, 2,410,933 unexercised pre-funded warrants were considered outstanding for purposes of the calculation of loss per share as of March 31, 2022. The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Options to purchase common stock 537,466 453,495 Series A Preferred — 158,545 Common stock warrants 6,539,011 58,688 Restricted stock units 22,881 8,451

Warrants

Warrants	3 Months Ended
	Mar. 31, 2022
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 13. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock, which have since been converted to common stock warrants. The Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share in connection with the SVB Term Loan (see Note 8). The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. In connection with the March 2022 Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 2,410,933 shares of common stock. Each pre-funded warrant has an exercise price of $0.001 per share and does not expire until exercised in full . The Company also issued and sold to the investor common warrants to purchase 3,244,987 shares of common stock that will expire on March 17, 2024 and common warrants to purchase an additional 3,244,987 shares of common stock that will expire on September 17, 2027. Each of these common warrants is exercisable commencing September 21, 2022 and has an exercise price of $2.062 per share. The following table shows the common stock warrants outstanding as of March 31, 2022: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 June 2020 42,894 11.6565 2030 March 2022 2,410,933 0.001 None March 2022 3,244,987 2.062 2024 March 2022 3,244,987 2.062 2027

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Deficit	Note 14. Stockholders’ Deficit Equity Offerings March 2022 Purchase Agreement In March 2022, the Company entered into a Securities Purchase Agreement (the “March 2022 Purchase Agreement”) with a single investor pursuant to which it agreed to issue to the investor 3,244,987 units at a price of $2.312 per unit (less $0.001 for each pre-funded warrant purchased in lieu of a share of common stock) for gross proceeds, before deducting the placement agent fees and other estimated fees and expenses, of approximately $7.5 million. Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of common stock with a term of 24 months from the issuance date, and a common warrant to purchase one share of common stock with a term of 66 months from the issuance date. Each of the common warrants is exercisable commencing on September 21, 2022 and has an exercise price of $2.062 per share. Each pre-funded warrant has an exercise price of $0.001 per share and does not expire until exercised in full. The pre-funded warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof. The common warrants issued in this transaction may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, which ownership cap may be increased by the holder up to 9.99% upon 61 days’ prior notice. Cantor Fitzgerald & Co. (“Cantor”) served as the placement agent in connection with the March 2022 Purchase Agreement. The Company has paid Cantor a fee of approximately $0.3 million plus reimbursement for certain out-of-pocket expenses for its role as placement agent and has incurred approximately $0.1 million of additional transaction costs. The securities issued to the investor under the March 2022 Purchase Agreement were offered in reliance on an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder. The Company relied on this exemption from registration based in part on representations made by the investor, including that the investor is an “accredited investor”, as defined in Rule 501(a) promulgated under the Securities Act. The securities sold pursuant to the March 2022 Purchase Agreement were subsequently registered for resale on a Form S-3 registration statement, filed with the SEC on April 8, 2022, which was declared effective by the SEC on April 19, 2022. Series A Preferred In March 2022, the remaining 23,770 shares of Series A convertible preferred stock (“Series A Preferred”) were converted by the holders into an aggregate of 158,466 shares of common stock. Accordingly, no shares of Series A Preferred are outstanding as of March 31, 2022. All of the previously designated Series A Preferred have resumed the status of authorized, unissued and undesignated preferred stock, which may be designated from time to time by the Company’s Board of Directors. Stock-based Compensation The Company incurs stock-based compensation expense relating to the grants of RSUs and stock options to employees, non-employee directors and consultants under its equity incentive plans and through stock purchase rights granted under the employee stock purchase plan. Stock-based compensation expense (including employee stock purchase plan expense) recorded in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 was as follows: Three Months Ended March 31, 2022 2021 Selling, general and administrative $ 192,903 $ 319,849 Research and development 66,904 23,234 Cost of product and product-related services revenue 7,998 7,856 $ 267,805 $ 350,939 Equity Compensation Plans In August 2020, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the 2020 Equity Incentive Plan (the “2020 Plan”) as a successor to and continuation of the 2014 Plan. Upon approval of the 2020 Plan, 744,685 shares of common stock, including 68,552 remaining shares reserved for issuance under the 2014 Plan (excluding shares available for the granting of inducement awards under the 2014 Plan’s inducement share pool), were reserved for issuance under the 2020 Plan. No new awards, including inducement awards, may be granted under the 2014 Plan. The 2020 Plan does not contain an evergreen provision. There were 580,735 shares of common stock available for issuance under the 2020 Plan (excluding shares available for granting of inducement awards under the 2021 Inducement Plan) as of March 31, 2022, in addition to shares that may become available from time to time as shares of the Company’s common stock subject to outstanding awards granted under the 2014 Plan (excluding inducement awards issued from the 2014 Plan’s inducement share pool), the 2011 Equity Incentive Plan (i) are not issued because such award or any portion thereof expires or otherwise terminates without all of the shares covered by such award having been issued; (ii) are not issued because such award or any portion thereof is settled in cash; or (iii) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. In July 2021, the Company’s Board of Directors adopted the Company’s 2021 Inducement Plan (the “2021 Inducement Plan”), pursuant to which 300,000 shares were initially authorized and reserved for issuance exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Company, as inducement material to the individuals’ entering into employment with the Company (“Inducement Awards”). There were 160,000 shares of common stock available for issuance under the 2021 Inducement Plan as of March 31, 2022, in addition to shares that may become available from time to time as shares of common stock subject to outstanding awards granted under the 2021 Inducement Plan are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. A summary of the Company’s stock option activity (including inducement award activity) for the three months ended March 31, 2022 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2021 559,336 $ 13.93 8.2 $ 30,267 Granted 29,500 3.74 Exercised - - Forfeited (17,494 ) 5.89 Expired/Cancelled (33,876 ) 34.94 Balance at March 31, 2022 537,466 $ 12.31 8.2 $ - Exercisable at March 31, 2022 283,983 $ 17.79 7.4 $ - As of March 31, 2022, total unrecognized compensation cost related to stock option awards was approximately $1.1 million, which is expected to be recognized over approximately 2.47 years. The following table summarizes restricted stock unit (“RSU”) award activity for the three months ended March 31, 2022: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2021 31,177 $ 6.93 Granted - - Released (4,148 ) 9.60 Forfeited - - Balance at March 31, 2022 27,029 6.52 Vested and unissued at March 31, 2022 4,148 $ 9.60 Vested and unissued awards at March 31, 2022 represents RSU awards for which the vesting date was March 31, 2022, but for which issuance of the awards occurred in April 2022

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Product Warranty The following is a summary of the Company’s general product warranty liability. Product warranty liability of approximately $0.1 million was included in accrued liabilities and an additional immaterial amount of product warranty liability was included in other non-current liabilities in the accompanying condensed consolidated balance sheets as of March 31, 2022. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying condensed consolidated statements of operations. Three Months Ended March 31, 2022 2021 Beginning balance $ 120,385 $ 92,696 Cost of warranty claims (15,005 ) (38,850 ) Increase in warranty reserve 19,820 28,417 Ending balance $ 125,200 $ 82,263

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
COVID-19 Pandemic	COVID-19 Pandemic The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the ongoing evolution of the COVID-19 pandemic, including resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes that while it has seen some recovery, this impact will continue to be seen at some level at least through the first half of 2022. The extent of this impact has varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization of studies by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has not experienced delays in its development efforts despite its efforts to prioritize the safety of its employees during this pandemic. In addition, the impact of the COVID-19 pandemic on the Company’s ability to source raw materials and other supplies has not been significant to date. However, a change in or loss of suppliers or other supply chain or distribution network partners due to the ongoing impacts of the pandemic on the global economy could adversely affect the Company’s business and the business of its vendors, partners and customers, and could result in future reductions in sales and operating results. While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date these condensed consolidated financial statements were issued and has reflected any known or expected impacts in its condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. As a result of various government programs enacted to address the ongoing impacts of COVID-19, the Company was able to qualify for and receive Employee Retention Credits (“ERC”) during the years ended December 31, 2020 and 2021. ERC benefits of approximately $0.1 million, $0.3 million, and $0.1 million were included in cost of product and product-related services revenue, selling, general and administrative and research and development, respectively, as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2021. In November 2021, the Infrastructure Investment and Jobs Act was signed into law, making wages paid after September 30, 2021 ineligible for these credits. As such, no further ERC benefits were received for the three months ended March 31, 2022. ERC benefits receivable of $0.4 million was included in prepaid expenses and other in the accompanying condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of March 31, 2022 and for the three months ended March 31, 2022 and 2021. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2022.
Going Concern and Liquidity	Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these financial statements. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $214.8 million as of March 31, 2022. As of March 31, 2022, the Company had working capital of $16.9 million and long-term liabilities of $8.7 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan with Silicon Valley Bank (the “SVB Term Loan”), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). Potentially changing circumstances, including COVID-19 uncertainties, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”). These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash, including short term investments available-for-sale, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, HTG Molecular Diagnostics France, SARL, after elimination of all intercompany transactions and balances.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instrument, related consumables, sample processing services and custom RUO assay design services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top three customers accounted for 24%, 20% and 12% of the Company’s revenue for the three months ended March 31, 2022, compared with the Company’s top two customers accounting for 19% and 15% of the Company’s revenue for the three months ended March 31, 2021. The largest three customers accounted for 50%, 11% and 10% of the Company’s accounts receivable as of March 31, 2022. The largest two customers accounted for approximately 18% and 17% of the Company’s accounts receivable as of December 31, 2021. The third and fourth largest customers accounted for approximately 10% each of the Company’s accounts receivable as of December 31, 2021. One vendor accounted for 28% of the Company’s accounts payable as of March 31, 2022, compared with two vendors who accounted for 28% and 16% of the Company’s accounts payable as of December 31, 2021. The Company is also subject to supply chain risks related to the reliance on a single supplier to manufacture a subcomponent used in its HTG EdgeSeq instruments. Although there are a limited number of manufacturers for components of this type, the Company believes that other suppliers could provide similar products on comparable terms. However, a change in or loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable, allowance for doubtful accounts and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 29, 2022.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The Company’s obligation related to an asset purchase transaction with a then-common stockholder of the Company, (the “NuvoGen obligation”) had an estimated fair value of approximately $4.2 million as of March 31, 2022. This estimated fair value represents a Level 3 measurement that has been determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates.
New Accounting Pronouncements	New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of March 31, 2022: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard became effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 Raw materials $ 1,952,440 $ 1,964,407 Work in process 264,553 312,803 Finished goods 622,206 447,145 Total gross inventory 2,839,199 2,724,355 Less inventory allowance (79,339 ) (25,306 ) $ 2,759,860 $ 2,699,049

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 in the fair value hierarchy: March 31, 2022 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 13,966,691 $ — $ — $ 13,966,691 Investments available-for-sale at fair value Corporate debt securities — 6,948,584 — 6,948,584 Total $ 13,966,691 $ 6,948,584 $ — $ 20,915,275 December 31, 2021 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 9,083,302 $ — $ — $ 9,083,302 Investments available-for-sale at fair value Corporate debt securities — 12,343,456 — 12,343,456 Total $ 9,083,302 $ 12,343,456 $ — $ 21,426,758

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities as of March 31, 2022 and December 31, 2021: March 31, 2022 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities $ 6,948,584 $ — $ — $ 6,948,584 Total available-for-sale securities $ 6,948,584 $ — $ — $ 6,948,584 December 31, 2021 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities $ 12,343,456 $ — $ — $ 12,343,456 Total available-for-sale securities $ 12,343,456 $ — $ — $ 12,343,456

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following as of the dates indicated: March 31, December 31, 2022 2021 Furniture & fixtures $ 872,877 $ 872,877 Leasehold improvements 1,940,177 1,931,762 Equipment used in manufacturing 2,432,242 2,432,242 Equipment used in research & development 2,343,930 2,343,930 Equipment used in the field 216,218 216,218 Software 480,740 480,740 Property and equipment 8,286,184 8,277,769 Less: accumulated depreciation and amortization (7,344,375 ) (7,158,883 ) $ 941,809 $ 1,118,886

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 Accrued employee bonuses $ 276,687 $ 1,254,355 Payroll and employee benefit accruals 286,526 389,385 Accrued accounting and legal fees 145,838 47,594 Accrued product warranty 98,716 97,512 Other accrued liabilities 217,217 233,723 $ 1,024,984 $ 2,022,569

Debt Obligations (Tables)

Debt Obligations (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Current Portion of Long-term Debt, Net	Current portion of long-term debt consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 SVB Term Loan $ 5,000,000 $ 5,000,000 2021 Insurance Note — 167,586 $ 5,000,000 $ 5,167,586
Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs	Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated: March 31, December 31, 2022 2021 SVB Term Loan, net of discount and debt issuance costs $ 4,046,356 $ 5,178,629
Schedule of Remaining Principal Repayments due Under SVB Term Loan	The remaining principal repayments due under the SVB Term Loan as of March 31, 2022 are as follows for each fiscal year: 2022 $ 3,750,000 2023 5,000,000 Total SVB Term Loan payments 8,750,000 Less discount and deferred financing costs (503,644 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 9,046,356

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-Related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three months ended March 31, 2022 and 2021 as follows: Three Months Ended March 31, 2022 2021 Product revenue: Instrument $ 193,186 $ 224,013 Consumables 471,214 604,382 Total product revenue 664,400 828,395 Product-related services revenue: Custom RUO assay design — 48,350 RUO sample processing 520,054 558,401 Total product-related services revenue 520,054 606,751 Total product and product-related services revenue $ 1,184,454 $ 1,435,146
Schedule of Changes in Contract Liability	Changes in the Company’s contract liability were as follows as of the dates indicated: Product Revenue Sample Processing Total Contract Liability Balance at January 1, 2022 $ 128,529 $ 30,621 $ 159,150 Deferral of revenue 147,893 - 147,893 Recognition of deferred revenue (102,812 ) (4,800 ) (107,612 ) Balance at March 31, 2022 $ 173,610 $ 25,821 $ 199,431

Other Agreements (Tables)

Other Agreements (Tables)	3 Months Ended
	Mar. 31, 2022
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	The remaining minimum payments to be made to NuvoGen as of March 31, 2022 are as follows for each fiscal year: 2022 $ 375,677 2023 472,624 2024 400,000 2025 400,000 2026 400,000 2027 and beyond 2,161,168 Total NuvoGen obligation payments 4,209,469 Plus interest accretion 64,105 Total NuvoGen obligation, net $ 4,273,574

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Summary of Components of Lease Cost	The components of lease cost for operating leases were as follows: Three Months Ended March 31, 2022 2021 Operating leases Operating lease cost $ 119,458 $ 167,679 Variable lease cost 27,526 26,151 Total rent expense $ 146,984 $ 193,830 The components of lease cost for financing leases were as follows: Three Months Ended March 31, 2022 2021 Financing leases Amortization of right-of-use assets $ 4,618 $ 7,099 Interest on lease liability 1,137 1,665 Total financing lease cost $ 5,755 $ 8,764
Summary of Other Information Related to Operating Leases	The table below summarizes other information related to the Company’s operating leases: Three Months Ended March 31, 2022 2021 Cash paid for amounts included in measurement of operating lease liabilities $ 117,952 $ 172,095 Weighted-average remaining lease term – operating leases 2.8 0.8 Weighted-average discount rate – operating leases 5.8 % 6.3 %
Summary of Remaining Maturities of Operating Leases	Remaining maturities of the Company’s operating leases, included in operating lease liabilities – current and other non-current liabilities, in the condensed consolidated balance sheets as of March 31, 2022 are as follows: 2022 $ 363,597 2023 484,719 2024 484,631 2025 40,381 Total 1,373,328 Less present value discount (108,812 ) Total operating lease liabilities 1,264,516 Less operating lease liabilities – current (423,111 ) Operating lease liabilities - non-current $ 841,405
Summary of Other Information Related to Financing Leases	The table below summarizes other information related to the Company’s financing leases: Three Months Ended March 31, 2022 2021 Weighted-average remaining lease term – financing leases 2.6 3.3 Weighted-average discount rate – financing leases 9.77 % 9.77 %
Summary of Remaining Maturities of Financing Leases	As of March 31, 2022, remaining maturities of the Company’s financing leases are as follows: 2022 $ 14,943 2023 18,396 2024 16,080 Total 49,419 Less present value discount (5,943 ) Financing lease liabilities, net $ 43,476

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Three Months Ended March 31, 2022 2021 Options to purchase common stock 537,466 453,495 Series A Preferred — 158,545 Common stock warrants 6,539,011 58,688 Restricted stock units 22,881 8,451

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2022
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the common stock warrants outstanding as of March 31, 2022: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 June 2020 42,894 11.6565 2030 March 2022 2,410,933 0.001 None March 2022 3,244,987 2.062 2024 March 2022 3,244,987 2.062 2027

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations	Stock-based compensation expense (including employee stock purchase plan expense) recorded in the accompanying condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 was as follows: Three Months Ended March 31, 2022 2021 Selling, general and administrative $ 192,903 $ 319,849 Research and development 66,904 23,234 Cost of product and product-related services revenue 7,998 7,856 $ 267,805 $ 350,939
Summary of Stock Option Plans Activity Including Inducement Award Activity	A summary of the Company’s stock option activity (including inducement award activity) for the three months ended March 31, 2022 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2021 559,336 $ 13.93 8.2 $ 30,267 Granted 29,500 3.74 Exercised - - Forfeited (17,494 ) 5.89 Expired/Cancelled (33,876 ) 34.94 Balance at March 31, 2022 537,466 $ 12.31 8.2 $ - Exercisable at March 31, 2022 283,983 $ 17.79 7.4 $ -
Summary of Restricted Stock Unit ("RSU") Award Activity	The following table summarizes restricted stock unit (“RSU”) award activity for the three months ended March 31, 2022: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2021 31,177 $ 6.93 Granted - - Released (4,148 ) 9.60 Forfeited - - Balance at March 31, 2022 27,029 6.52 Vested and unissued at March 31, 2022 4,148 $ 9.60

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability Three Months Ended March 31, 2022 2021 Beginning balance $ 120,385 $ 92,696 Cost of warranty claims (15,005 ) (38,850 ) Increase in warranty reserve 19,820 28,417 Ending balance $ 125,200 $ 82,263

Description of Business, Basi_2

Description of Business, Basis of Presentation and Principles of Consolidation - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022USD ($)SegmentCustomer	Mar. 31, 2021USD ($)Customer	Dec. 31, 2021USD ($)Customer
Significant Accounting Policies [Line Items]
Number of operating segments | Segment	1
Employee retention credit benefits	$ 0
Employee retention credits benefits receivable	400,000		$ 400,000
Accumulated deficit	(214,830,550)		$ (208,333,031)
Working capital	16,900,000
Long-term liabilities	8,700,000
Debt instrument, covenant unrestricted cash	$ 12,500,000
SVB Term Loan | Minimum
Significant Accounting Policies [Line Items]
Debt instrument, interest at floating rate	5.00%
Cost of Product and Product-related Services Revenue
Significant Accounting Policies [Line Items]
Employee retention credit benefits		$ 100,000
Selling, General and Administrative
Significant Accounting Policies [Line Items]
Employee retention credit benefits		300,000
Research and Development
Significant Accounting Policies [Line Items]
Employee retention credit benefits		$ 100,000
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer	3	2
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage	18.00%	41.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage	12.00%
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	24.00%	19.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage	20.00%	15.00%
Accounts Payable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer	1		2
Accounts Payable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	28.00%		28.00%
Accounts Payable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			16.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer	3		2
Accounts Receivable | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage	10.00%		10.00%
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage	50.00%		18.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage	11.00%		17.00%
Accounts Receivable | Customer Concentration Risk | Customer Four
Significant Accounting Policies [Line Items]
Sales revenue percentage			10.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Millions	Mar. 31, 2022USD ($)
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Convertible debt, fair value	$ 4.2

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 1,952,440	$ 1,964,407
Work in process	264,553	312,803
Finished goods	622,206	447,145
Total gross inventory	2,839,199	2,724,355
Less inventory allowance	(79,339)	(25,306)
Inventory, net	$ 2,759,860	$ 2,699,049

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Inventory [Line Items]
Inventory, net of allowance of $79,339 at March 31, 2022 and $25,306 at December 31, 2021	$ 2,022,478		$ 1,987,753
Inventory reserve	54,033
Provision for excess inventory	5,320	$ 4,836
Finished goods inventory	622,206		447,145
HTG EdgeSeq
Inventory [Line Items]
Finished goods inventory	200,000		200,000
Inventory Net
Inventory [Line Items]
Inventory, net of allowance of $79,339 at March 31, 2022 and $25,306 at December 31, 2021	2,000,000		2,000,000
Other Noncurrent Assets
Inventory [Line Items]
Inventory, noncurrent	$ 700,000		$ 700,000

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Asset included in:
Investments available-for-sale at fair value	$ 6,948,584	$ 12,343,456
Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	6,948,584	12,343,456
Fair Value, Measurements, Recurring
Asset included in:
Financial Assets	20,915,275	21,426,758
Fair Value, Measurements, Recurring | Money Market Securities
Asset included in:
Cash and cash equivalents	13,966,691	9,083,302
Fair Value, Measurements, Recurring | Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	6,948,584	12,343,456
Fair Value, Measurements, Recurring | Level 1
Asset included in:
Financial Assets	13,966,691	9,083,302
Fair Value, Measurements, Recurring | Level 1 | Money Market Securities
Asset included in:
Cash and cash equivalents	13,966,691	9,083,302
Fair Value, Measurements, Recurring | Level 2
Asset included in:
Financial Assets	6,948,584	12,343,456
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	$ 6,948,584	$ 12,343,456

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 6,948,584	$ 12,343,456
Gross Unrealized Losses	0
Fair Value (Net Carrying Amount)	6,948,584	12,343,456
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,948,584	12,343,456
Fair Value (Net Carrying Amount)	$ 6,948,584	$ 12,343,456

Available-for-Sale Securities_2

Available-for-Sale Securities - Additional Information (Details)	Mar. 31, 2022USD ($)
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities investments, gross unrealized losses	$ 0

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 872,877	$ 872,877
Leasehold improvements	1,940,177	1,931,762
Equipment used in manufacturing	2,432,242	2,432,242
Equipment used in research & development	2,343,930	2,343,930
Equipment used in the field	216,218	216,218
Software	480,740	480,740
Property and equipment	8,286,184	8,277,769
Less: accumulated depreciation and amortization	(7,344,375)	(7,158,883)
Property and equipment, net	$ 941,809	$ 1,118,886

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 185,492	$ 197,951

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 276,687	$ 1,254,355
Payroll and employee benefit accruals	286,526	389,385
Accrued accounting and legal fees	145,838	47,594
Accrued product warranty	98,716	97,512
Other accrued liabilities	217,217	233,723
Total accrued liabilities	$ 1,024,984	$ 2,022,569

Debt Obligations - Schedule of

Debt Obligations - Schedule of Current Portion of Long Term Debt, Net (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Current portion of long-term debt, net	$ 5,000,000	$ 5,167,586
SVB Term Loan
Debt Instrument [Line Items]
SVB Term Loan	$ 5,000,000	5,000,000
2020 Insurance Note
Debt Instrument [Line Items]
Insurance note		$ 167,586

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
SVB Term Loan
Debt Instrument [Line Items]
Loan, net of discount and debt issuance costs	$ 4,046,356	$ 5,178,629

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details) - USD ($)	May 05, 2021	Jun. 24, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument, covenant unrestricted cash			$ 12,500,000
Insurance Note
Debt Instrument [Line Items]
Debt instrument, interest rate	3.57%
Debt instrument, maturity date	Jun. 30, 2021
Down payment on insurance note	$ 400,000
Premium payable on insurance note	$ 700,000
Loan term	9 months
SVB Term Loan
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 10,000,000
Debt instrument, interest rate		5.75%
Extend the interest-only payments		6 months
Debt instrument, maturity date		Dec. 1, 2023
Warrant to purchase common stock, shares		42,894
Warrant purchase price		$ 11.6565	$ 11.6565
Warrant expiration date		Jun. 24, 2030
Fair value of warrants		$ 400,000
Debt instrument, amortization expense			$ 100,000	$ 100,000
Debt discount, fees and debt issuance costs			$ 503,644		$ 600,000
SVB Term Loan | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate			5.00%
SVB Term Loan | Prime Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate		2.50%

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Remaining Principal Repayments due Under SVB Term Loan (Details) - SVB Term Loan - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
2022	$ 3,750,000
2023	5,000,000
Total SVB Term Loan payments	8,750,000
Less discount and deferred financing costs	(503,644)	$ (600,000)
Plus final fee premium	800,000
Total SVB Term Loan, net	$ 9,046,356

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 1,184,454	$ 1,435,146
HTG EdgeSeq | Instrument
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	193,186	224,013
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	471,214	604,382
HTG EdgeSeq | Product revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	664,400	828,395
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue		48,350
HTG EdgeSeq | RUO Sample processing
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	520,054	558,401
HTG EdgeSeq | Product-related services revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	520,054	606,751
HTG EdgeSeq | Product and product-related services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 1,184,454	$ 1,435,146

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue, description	the Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Other Current Liabilities
Disaggregation Of Revenue [Line Items]
Contract liabilities – current	$ 0.2
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term	30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information1 (Details)	Mar. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-04-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Schedule of Changes in Contract Liability (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 159,150
Deferral of revenue	147,893
Recognition of deferred revenue	(107,612)
Ending Balance	199,431
Product Revenue
Disaggregation Of Revenue [Line Items]
Beginning Balance	128,529
Deferral of revenue	147,893
Recognition of deferred revenue	(102,812)
Ending Balance	173,610
Sample Processing
Disaggregation Of Revenue [Line Items]
Beginning Balance	30,621
Recognition of deferred revenue	(4,800)
Ending Balance	$ 25,821

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)
Other Agreements [Line Items]
Accretion of discount on NuvoGen obligation	$ (2,983)	$ (3,106)
Measurement Input, Default Rate
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid	6.00%
Asset purchase agreement yearly fixed fees paid	$ 400,000
Asset purchase agreement fixed quarterly payments	100,000
Additional revenue based amount payable	0
Additional revenue based payments payable			$ 72,624
NuvoGen
Other Agreements [Line Items]
Unamortized interest accretion	(64,105)		$ (67,088)
Accretion of discount on NuvoGen obligation	$ (2,983)	$ (3,106)

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Mar. 31, 2022USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2022	$ 375,677
2023	472,624
2024	400,000
2025	400,000
2026	400,000
2027 and beyond	2,161,168
Total NuvoGen obligation payments	4,209,469
Plus interest accretion	64,105
Total NuvoGen obligation, net	$ 4,273,574

Leases - Additional Information

Leases - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Leases [Abstract]
Operating lease, description	The Company’s active leases as of March 31, 2022 are for office and manufacturing space in Tucson, Arizona, which expire in 2025.
Lease expiration year	2025
Financing lease liabilities, current	$ 16,038
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities
Financing lease liabilities, non current	$ 27,438
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities
Financing leases, right-of-use assets	$ 39,034

Leases - Summary of Components

Leases - Summary of Components of Lease Cost for Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease cost	$ 119,458	$ 167,679
Variable lease cost	27,526	26,151
Total rent expense	$ 146,984	$ 193,830

Leases - Summary of Other Infor

Leases - Summary of Other Information Related to Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Cash paid for amounts included in measurement of operating lease liabilities	$ 117,952	$ 172,095
Weighted-average remaining lease term – operating leases	2 years 9 months 18 days	9 months 18 days
Weighted-average discount rate – operating leases	5.80%	6.30%

Leases - Summary of Remaining M

Leases - Summary of Remaining Maturities of Operating Leases (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2022	$ 363,597
2023	484,719
2024	484,631
2025	40,381
Total	1,373,328
Less present value discount	(108,812)
Total operating lease liabilities	1,264,516
Less operating lease liabilities – current	(423,111)	$ (413,865)
Operating lease liabilities - non-current	$ 841,405

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost for Financing Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Amortization of right-of-use assets	$ 4,618	$ 7,099
Interest on lease liability	1,137	1,665
Total financing lease cost	$ 5,755	$ 8,764

Leases - Summary of Other Inf_2

Leases - Summary of Other Information Related to Financing Leases (Details)	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Weighted-average remaining lease term – financing leases	2 years 7 months 6 days	3 years 3 months 18 days
Weighted-average discount rate – financing leases	9.77%	9.77%

Leases - Summary of Remaining_2

Leases - Summary of Remaining Maturities of Financing Leases (Details)	Mar. 31, 2022USD ($)
Leases [Abstract]
2022	$ 14,943
2023	18,396
2024	16,080
Total	49,419
Less present value discount	(5,943)
Financing lease liabilities, net	$ 43,476

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - Pre Funded Warrants	Mar. 31, 2022$ / sharesshares
Class Of Warrant Or Right [Line Items]
Exercise price of warrants | $ / shares	$ 0.001
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants | shares	2,410,933
Exercise price of warrants | $ / shares	$ 0.001
Warrant to purchase common stock | shares	2,410,933

Net Loss per Share - Common Sto

Net Loss per Share - Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	537,466	453,495
Warrants | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	6,539,011	58,688
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	22,881	8,451
Series A Preferred
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		158,545

Warrants - Additional Informati

Warrants - Additional Information (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Jun. 24, 2020
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants		42,894
Exercise price of warrants	$ 11.6565	$ 11.6565
Warrant expire date	Jun. 24, 2030
Warrant to purchase common stock	42,894
Pre Funded Warrants
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 0.001
Pre Funded Warrants | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 0.001
Investor | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants	3,244,987
Exercise price of warrants	$ 2.062
Minimum | SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant to purchase common stock	42,894
Minimum | Investor | Pre Funded Warrants | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 0.001
Private Placement | Investor | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 2.062
Warrant exercisable commencing date	Sep. 21, 2022
Private Placement | Investor | Pre Funded Warrants | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants	2,410,933
Exercise price of warrants	$ 0.001
Private Placement | Investor | Warrant Expiring in March 17, 2024 | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants	3,244,987
Warrant expire date	Mar. 17, 2024
Private Placement | Investor | Warrant Expiring in September 17, 2027 | March 2022 Purchase Agreement
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants	3,244,987
Warrant expire date	Sep. 17, 2027

Warrants -Summary of Warrants O

Warrants -Summary of Warrants Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Jun. 24, 2020
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-08
Shares of Common Stock Underlying Warrants	1,914
Exercise Price/Share	$ 352.65
Expiration Date	2024
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2016-03
Shares of Common Stock Underlying Warrants	3,021
Exercise Price/Share	$ 41.40
Expiration Date	2026
Common Stock Tranche One
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2018-03
Shares of Common Stock Underlying Warrants	1,208
Exercise Price/Share	$ 115.95
Expiration Date	2028
Common Stock Tranche Two
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2022-03
Shares of Common Stock Underlying Warrants	2,410,933
Exercise Price/Share	$ 0.001
Common Stock Tranche Three
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2022-03
Shares of Common Stock Underlying Warrants	3,244,987
Exercise Price/Share	$ 2.062
Expiration Date	2024
Common Stock Tranche Four
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2022-03
Shares of Common Stock Underlying Warrants	3,244,987
Exercise Price/Share	$ 2.062
Expiration Date	2027
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2020-06
Shares of Common Stock Underlying Warrants	42,894
Exercise Price/Share	$ 11.6565	$ 11.6565
Expiration Date	2030

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022	Jul. 31, 2021	Aug. 31, 2020
Employee Stock Option
Class Of Stock [Line Items]
Unrecognized compensation expense	$ 1.1
Compensation expense period expected to be recognized	2 years 5 months 19 days
Restricted Stock Units
Class Of Stock [Line Items]
Unrecognized compensation expense	$ 0.1
Compensation expense period expected to be recognized	1 year 3 months 25 days
Vested and unissued RSU awards, description	Vested and unissued awards at March 31, 2022 represents RSU awards for which the vesting date was March 31, 2022, but for which issuance of the awards occurred in April 2022.
Vested and unissued RSU awards vesting date	Mar. 31, 2022
Vested and unissued RSU awards issuance date	Apr. 30, 2022
2020 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance			744,685
Number of shares available for issuance	580,735
2014 Equity Incentive Plan
Class Of Stock [Line Items]
Shares reserved for issuance			68,552
Number of shares available for issuance			0
2021 Inducement Plan
Class Of Stock [Line Items]
Shares reserved for issuance		300,000
Number of shares available for issuance	160,000
Common Stock
Class Of Stock [Line Items]
Conversion of Series A convertible preferred stock for common stock, shares	158,466
Series A Preferred
Class Of Stock [Line Items]
Preferred stock, shares converted	23,770
Preferred stock, shares outstanding	0
March 2022 Purchase Agreement
Class Of Stock [Line Items]
Warrant issuance, description	Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of common stock with a term of 24 months from the issuance date, and a common warrant to purchase one share of common stock with a term of 66 months from the issuance date.
Percentage Of Minimum Aggregate Number Of Shares Beneficially Owned By Holder	4.99%
Percentage Increase In Ownership Cap	9.99%
Pre Funded Warrants
Class Of Stock [Line Items]
Exercise price of warrants	$ 0.001
Pre Funded Warrants | March 2022 Purchase Agreement
Class Of Stock [Line Items]
Exercise price of warrants	$ 0.001
Percentage Of Minimum Aggregate Number Of Shares Beneficially Owned By Holder	9.99%
Investor | March 2022 Purchase Agreement
Class Of Stock [Line Items]
Exercise price of warrants	$ 2.062
Gross Proceeds From Issuance Of Warrants	$ 7.5
Number of securities called by warrants	3,244,987
Investor | Minimum | Pre Funded Warrants | March 2022 Purchase Agreement
Class Of Stock [Line Items]
Exercise price of warrants	$ 0.001
Cantor Fitzgerald And Co | March 2022 Purchase Agreement
Class Of Stock [Line Items]
Agent fee	$ 0.3
Additional transaction costs	$ 0.1

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of Stock-Based Compensation Recorded in Condensed Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 267,805	$ 350,939
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	192,903	319,849
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	66,904	23,234
Cost of Product and Product-related Services Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,998	$ 7,856

Stockholders' Deficit - Summa_2

Stockholders' Deficit - Summary of Stock Option Plans Activity Including Inducement Award Activity (Details) - Employee Stock Option - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	559,336
Number of Shares, Granted	29,500
Number of Shares, Forfeited	(17,494)
Number of Shares, Expired/Cancelled	(33,876)
Number of Shares, Ending Balance	537,466	559,336
Number of Shares, Exercisable	283,983
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 13.93
Weighted-Average Exercise Price Per Share, Granted	3.74
Weighted-Average Exercise Price Per Share, Forfeited	5.89
Weighted-Average Exercise Price Per Share, Expired/Cancelled	34.94
Weighted-Average Exercise Price Per Share, Ending Balance	12.31	$ 13.93
Weighted-Average Exercise Price Per Share, Exercisable	$ 17.79
Weighted-Average Remaining Contractual Life, Outstanding	8 years 2 months 12 days	8 years 2 months 12 days
Weighted-Average Remaining Contractual Life, Exercisable	7 years 4 months 24 days
Aggregate Intrinsic Value, Balance		$ 30,267

Stockholders' Deficit - Summa_3

Stockholders' Deficit - Summary of Restricted Stock Unit ('RSU') Award Activity (Details) - Restricted Stock Units	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Restricted Stock Units (RSU)
Beginning Balance | shares	31,177
Released | shares	(4,148)
Ending Balance | shares	27,029
Vested and unissued at March 31, 2022 | shares	4,148
Weighted Average Grant Date Fair Value Per Share
Beginning Balance | $ / shares	$ 6.93
Released | $ / shares	9.60
Ending Balance | $ / shares	6.52
Vested and unissued at March 31, 2022 | $ / shares	$ 9.60

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Product Warranty Liability [Line Items]
Accrued product warranty	$ 98,716	$ 97,512
Accrued Liabilities
Product Warranty Liability [Line Items]
Accrued product warranty	$ 100,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary Of Product Warranty Liability (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 120,385	$ 92,696
Cost of warranty claims	(15,005)	(38,850)
Increase in warranty reserve	19,820	28,417
Ending balance	$ 125,200	$ 82,263